<SEC-DOCUMENT>0001274737-21-000085.txt : 20210730
<SEC-HEADER>0001274737-21-000085.hdr.sgml : 20210730
<ACCEPTANCE-DATETIME>20210730082519
ACCESSION NUMBER:		0001274737-21-000085
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210729
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210730
DATE AS OF CHANGE:		20210730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		211130188

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xgnxdirectorappointment7x2.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8abd2d213f174a45bec68f8cdeb71b73_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM 8-K </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)&#58; July 29, 2021 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">EXAGEN INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:32.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.601%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">001-39049</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20-0434866</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of incorporation)</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Commission</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Number)</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</font></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1261 Liberty Way </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vista, CA 92081 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code) </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(760) 560-1501 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N&#47;A </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report) </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58; </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.749%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.140%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:81.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act&#58; </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.045%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Symbol(s)</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">on which registered</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock, par value $0.001 per share</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">XGN</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Nasdaq Global Market</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746; </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744; </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02. Departure of Directors or Certain Officers&#59; Election of Directors&#59; Appointment of Certain Officers&#59; Compensatory Arrangements of Certain Officers. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2020, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the &#34;Board&#34;) of Exagen Inc. (the &#34;Company&#34;), and pursuant to the bylaws of the Company, the Board approved an increase in its authorized size from eight members to nine members and appointed Ana Hooker to fill the vacancy created by such increase and serve as a Class II director, with an initial term expiring at the Company's 2024 annual meeting of stockholders. The increase and appointment were effective as of July 29, 2021.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ana Hooker has served as the Senior Vice President, Operations of Exact Sciences Corporation, a molecular diagnostics company, since July 2015. Ms. Hooker joined Exact Sciences Corporation in March 2013 with a focus on opening a new clinical laboratory in preparation for the launch of Cologuard. Prior to joining Exact Sciences Corporation, Ms. Hooker was at ARUP Laboratories for 15 years. While at ARUP Laboratories, Ms. Hooker held positions of increasing responsibility, including Group Manager for the Divisions of Oncology and Genetics, Technical Supervisor of the University of Utah Hospital Clinical Laboratories, Vice President, Division Manager for genetics and Senior Vice President, Division Manager for anatomic pathology, oncology and genetics. Ms. Hooker currently serves on the boards of Big Brothers, Big Sisters of Dane County and the Overture Center for the Arts. Ms. Hooker is also a member of the Latino Professional Association (LPA), Clinical Laboratory Management Association (CLMA), Association of Molecular Pathology (AMP), and the American Society of Clinical Laboratory Science (ASCLS). Ms. Hooker earned a Bachelor of Science from Kansas State University, a medical technologist degree from Hays Pathology Laboratories, and an M.B.A. from Westminster College.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company's non-employee director compensation program, on the effective date of Ms. Hooker's appointment to the Board, she was granted an option to purchase 15,000 shares of the Company's common stock with an exercise price equal to the fair market value of the common stock on the date of grant, which will vest over three years in equal installments on each monthly anniversary of the grant date, subject to her continuing service on the Board through the applicable vesting date. Ms. Hooker will also receive cash compensation for her service on the Board in accordance with the non-employee director compensation program, which is filed as </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1038.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 10.4</a><a href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1038.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Company's Annual Report on Form 10-K, filed with the SEC on March 16, 2021 and is incorporated herein by reference. Ms. Hooker will enter into the Company's standard indemnification agreement for directors, the form of which was filed as </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 10.</a><a href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">41</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Company's Annual Report on Form 10-K, filed with the SEC on March 16, 2021 and is incorporated herein by reference.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no arrangement or understanding between Ms. Hooker and any other person pursuant to which Ms. Hooker was appointed as a director. Ms. Hooker is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The Board has determined that Ms. Hooker is an independent director in accordance with the listing requirements of the Nasdaq Global Market.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01. Other Events. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, the Company issued a press release announcing the appointment of Ms. Ana Hooker as a director, a copy of which is attached hereto as Exhibit 99.1, and is incorporated by reference herein.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.103%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="anahookerbodpressrelease-7.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release dated July 30, 2021</a></font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:43.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.652%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.947%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 30, 2021</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>anahookerbodpressrelease-7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i42bb3294a6544b399a897048d3c8968f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:171px"></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:145%">Exagen Appoints Ana Hooker to Board of Directors</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">July 30, 2021</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">SAN DIEGO &#8211; Exagen Inc. (Nasdaq&#58; XGN), a leading provider of autoimmune testing solutions, is proud to announce the addition of Ms. Ana Hooker as an additional independent member to its Board of Directors, effective July 29, 2021.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#8220;We are excited to welcome Ms. Hooker to our Board of Directors,&#8221; said Ron Rocca, Exagen&#8217;s President and Chief Executive Officer. &#8220;Ana&#8217;s extensive experience in life sciences, and in particular, clinical laboratories, will play a key role in Exagen&#8217;s continued expansion.&#8221;  </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#8220;I am excited to join the board of such an innovative company that is having a real impact on patient&#8217;s lives through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases,&#8221; said Ms. Hooker.  &#8220;Exagen has a world-class laboratory, a robust pipeline   and I look forward to working with the executive leadership team and board of directors, as the Company continues to execute on its compelling mission and growth strategy.&#8221;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Ana Hooker has served as the Senior Vice President, Operations of Exact Sciences Corporation, a molecular diagnostics company, since July 2015. Ms. Hooker joined Exact Sciences Corporation in March 2013 with a focus on opening a new clinical laboratory in preparation for the launch of Cologuard. Prior to joining Exact Sciences Corporation, Ms. Hooker was at ARUP Laboratories for 15 years. While at ARUP Laboratories, Ms. Hooker held positions of increasing responsibility, including Group Manager for the Divisions of Oncology and Genetics, Technical Supervisor of the University of Utah Hospital Clinical Laboratories, Vice President, Division Manager for genetics and Senior Vice President, Division Manager for anatomic pathology, oncology and genetics. Ms. Hooker currently serves on the boards of Big Brothers, Big Sisters of Dane County and the Overture Center for the Arts. Ms. Hooker is also a member of the Latino Professional Association (LPA), Clinical Laboratory Management Association (CLMA), Association of Molecular Pathology (AMP), and the American Society of Clinical Laboratory Science (ASCLS). Ms. Hooker earned a Bachelor of Science from Kansas State University, a medical technologist degree from Hays Pathology Laboratories, and an M.B.A. from Westminster College.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Exagen</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">under its AVISE&#174; brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen&#8217;s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For more information, please visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%;text-decoration:underline">www.Exagen.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:145%">Forward Looking Statements</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Exagen cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the Exagen's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding Exagen&#8217;s goals and strategies, the potential utility and effectiveness of Exagen&#8217;s services and testing solutions, Exagen&#8217;s potential growth and expansion and management&#8217;s views and expectations of the same. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from  those set forth in this press release due to the risks and uncertainties inherent in Exagen&#8217;s business, including, without limitation&#58; the COVID&#8209;19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving our tests&#59; the company&#8217;s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community&#59; the company&#8217;s ability to successfully execute on its business strategies&#59; third party payers not providing coverage and adequate reimbursement for the company&#8217;s testing products or promoted therapeutics&#59; the company&#8217;s ability to obtain and maintain intellectual property protection for its testing products&#59; regulatory developments affecting the company&#8217;s business&#59; and other risks described in the company&#8217;s prior press releases and Exagen&#8217;s filings with the Securities and Exchange Commission (SEC), including under the heading &#8220;Risk Factors&#8221; in the company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 on and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">CONTACTS&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Investor Relations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exagen Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Ryan Douglas</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">rdouglas&#64;exagen.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">760.560.1525</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Company</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exagen Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Kamal Adawi, Chief Financial Officer</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">kadawi&#64;exagen.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">760.477.5514</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8@# 2(  A$! Q$!_\0
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MIXF4L-AZLO9QIMU(IMQ\M+VOZ(^W***,UH?J@4444 %%%% !111F@ HHS10
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MJ37N7[/7_!TOKD-Q#IO[5O[-%M/&TSFZUSX?7S1M%'CY52QO'?>V>K&Z08Y
M['ZZU+_@WU_X):7_ (:FT.V^ VI65U):>5'K5KXTU0W43[<><JR7+P[\_-@Q
M%,_PXXKYA_:(_P"#6KPI-I<FI?LG_M):E;7<-F!'HWQ#LX[B*[N/,Y)O+..,
MVZ;#T^SS$LO4!OEYECN#<9+DE2<.E]OGHW^*]3>6%XJPGOQFI^6C_-+\S]*O
MV8?VM/V?OVROALOQ5_9V^(=OK^DK=-;73)%)#/:3J 6BFAE59(GP01N4!E(9
M258$^&_\%5O^"IQ_X)DZ7X+U*/X%_P#";_\ "7W%]#Y?_"3?V;]D^S+ V?\
MCVF\S=YW^SC;WSQ^%NCS?MI_\$G_ -J:R\176@:QX'\9:'-((X]3LW^QZS9B
M0I(F>$O+24H1N0E25#*RNBLOU=_P6F_;9\%?M\?L@_L_?'?PG:1:?=RZGKUM
MX@T/[<D\FEWR1V(DA8K\P!X>,N$9HW1BHW5C'ANC2S*BT_:4)NUT_*]FU;[T
M:RXBJU,!43]RK#RW^_\ (_13_@E1_P %;W_X*;ZQXVTO_A0 \$_\(?;V$OF#
MQ5_:7VO[2UP,?\>L/E[?(_VMV[^''/V8>F2*_&O_ (-4"?\ A,?C6/\ J&Z!
M_P"AW]?LHWW<9_$U\_GV$HX'-JE&DK1CTNWNO-MGN9)BJV,RV%6H[R=];6_X
M UFV]QQZU\C_ +;7_!:;]B?]B+4[CP1XA\6W7B_QE"_EW'A7P?&EQ-9MB4?Z
M5,SK!;E7B"O'O:=?,1O)*G=7RO\ \%NO^"U?BCX0^)+[]D/]CGQS9PZS%:RV
MGCKQ?IS%[C29V.UK&UD!"QW*+GS)5W-$SA5:.:-MOY+_ +._[-/QV_:T^)L7
MPA_9Z^'=[XH\0S6LUV;.UFCC6*"/EY99IG2*%,E5W2.JEW1 =[H&][)N%H5L
M/];Q\N2GNELVO-O9?F>1FO$DZ5;ZO@US3V?57[)+<_0CXI?\'2?[4&L:_#<_
M!;]G#P+X?TI;-5GLO$UU>ZO<//O;,BS026:K&5* (8R058[V#!5\_P!)_P"#
ME'_@HYIWBBZ\0WEO\/[ZTN%Q#H=UX7E6UMN!RACN$G/3^.5NI]L?1G[-_P#P
M:V: NB+J?[7/[1=]+J$UNZMH?PYA2&&UF$IV/]MO8G,ZF( E?LT15V(#,JY?
MZ(M/^#=/_@F7;_#'_A 9_ ?BB;5C;/'_ ,)Q)XNN?[3W,Y82[%(LMR@A0/LV
MW"C*DY8]L\=P7AGR0HN72]F_QDT_N.*&!XJQ'ORJ<O75_P"2T/EC]G?_ (.E
MO%=I<Q:7^U?^S38WD,E\YFUSX>WSV[6]OY8VJMC>/()I/,!R_P!JC7:XPN4)
M?]-_V/?VY/V;/VZ/ +?$']G?QZFI+:+"-:TFZA,%]I,TD>\0W$+=#]Y0ZEHG
M,<GENX0D?GS\>_\ @UH^%U[H'VG]F#]I;Q!INJ6]I<$V/CRU@OH;^XVKY">?
M:1P-:)D,';RKAL,"%&TJ_P";/CWX9?MM?\$HOVF[>[U2#6/!/BK0]0<Z+XBT
M]9#8:Q%&4)>WE91'>VSJ\>^-@0 _ERHK;D&<LIX?SJ#_ +/GR5%]EWU^_P#1
MFD<RSO*)KZ['GAWTT^:_4_;[_@JS_P %;3_P3(UCP5I,?P _X3?_ (3"WOY/
M,_X2G^S?LGV9H!C'V6?S-WG]?EV[?XL\8/\ P2U_X+1R?\%*/C1KWPC;]FT>
M"_[#\,MJ_P#:'_"7_P!H^=BXAA\K9]CAV_ZW=NW'[N,<Y'YD_P#!77]OKPE_
MP4'^"_P#^*$$NEVGB[3]/UVU\<>'=-N';^S;SS++:P60!Q%,J^;']\#YHQ)(
MT3FO4/\ @UR&[]LSQYD?\TUE_P#3C:5%3(,+A^&YXFK3M5BVF[OH[;7M^ 4\
M\Q.(SR%&G.].72RZKO:_XG[H9)Y6AN%Y';M00JC.*_(S_@MO_P %M)/#<NK_
M +&O['7BT?VAA[/QQXWTV8YL^JR6%HZ])>JR3*?W?**0^YH_D\MR[%9IBE1H
MK7J^B7=L^IS#,,/EV'=2H_1=6^Q]:_MN_P#!:[]C#]AOQ;/\+O%^K:MXK\86
MNT7WAOPC9I,]@6C+I]IFE>.&//RY17:50ZL8]I!K\]_B9_P=)?M6:OXD^T_!
M_P#9W\ Z!I'V=1]A\137VK7/F\[F\^&6T7:>,+Y61@Y8YX^3/V%?^"7?[5O_
M  4 U??\)/"D>F^&[>9H]0\:>(!)!IL#J 6B1T5FGFP1^[C5L;EW%%.X?K/^
MSM_P;7?L)_#/34D^.6H^(_B=JDEIY=U]NU232K%)-^?-@@LG29#MPNV2XE7J
M< D8^PJ8/A?)5R8ANK4ZI?\ #V^39\I#%<19Q>5!>SAT?]*[^X^#] _X.4O^
M"CNDZ]>:QJ$'P_U.WN3^YTJ^\,RK!:_[AAN(Y3_P.1Z]D_9^_P"#I3XCV6KK
M9_M4?LUZ/J%C->)NU+X?WDMI-9P;3O\ ]%O))5N7SC&9X0!GKUK[<;_@@9_P
M2=\OC]E=O_"ZUW_Y.KYQ_:S_ .#8WX(>+=/U#Q-^QW\4-2\)ZPTCRV?AOQ-,
M;[22-H @28)]J@&?F,CM<GMMQR(_M#@_&2Y)T'#SV_)O\O4J6!XJPL>>%52\
MM_S2/M_]C+_@H9^RO^WCX>FUC]GSX@_:K^PA235_#NHVYM]0T\-P/,B8X9<\
M>9&7CSP&)XKW+!SFOY1_B-\.?VC_ -@;]HYO#/B:'5/!OCOP=J*W%E?6LQ5@
MP.8[F"1>)(G'(895@2"/O+7[M_\ !(7_ (*Y^#/V_O!<?PX^)$]GHWQ6T6S#
M:IIBD1Q:S"HP;RU![=Y(ADQDY&4((\W/.&Y8&E]:PLN>D^N]O5K=>9Z.3\0?
M7*CH8F/)4_!_Y>A]N.2%XKY;^+7_  69_P"";OP/^)6L_"/XH?M'?V9X@\/W
MSV>L:?\ \(?K$_D3+]Y?,BLW1L>JLP/8U]2'..G:OY@/^"K_ /RD?^,W./\
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M"NTD&.WEM+=)"6V@@S)@$D$D!3C6W_!J1=20(UU^W;'')M!D5/AB6"MW /\
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M\;ZCP7_S_?WO_(]7Z_Q9_P ^_P %_F?7W_$4/^P=_P!$>^+W_@CTK_Y8T?\
M$4/^P=_T1[XO?^"/2_\ Y8U\@_\ $+_^W[_T5;X1?^%!JO\ \KJ#_P &O_[?
MO_15OA%_X4&J_P#RNI?4>"_^?[^]_P"0?7^+/^??X+_,_9[]EC]HWP3^UK\
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M_@G[\";#X4?#RWBU#6)HTD\5>+9+%(;K6KKDF1]N2(U+LL419O+3C<S%W?\
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M*CBI2NXOYIZGVM/$86G%14X^EUL>R_/[4C;]IZ5X[_P\3_X)_?\ 1[WPC_\
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M3XHT&UU/3YI(6C9X9XED0E3RI(8?*>175 5\G_\ !$?XE^(/BI_P3'^%NO\
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M#CAM]7;YM'C^RE5X17+T=_N>IRO_  :F?\AWXX\?\NOAO^>I5^QX/%?S[_\
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MI?C;0? -I);SP7S> =)DM[B[60* 3<7,MQ- Z '8]N\3#>Q))V[>7_X)T?\
M!+?]H_\ X*:_$*^\<WNJ7&E^$(=2\[Q5X^U_S)FOKAY-TL5N6YN[IMS.Y+!4
MSEW4NBOW87A>&7P^LYG)1C'[*>K?;_@*]SBQ7$53'2^KY?%N4OM-;>A\U>*]
M ^(FI:);_&GQFUU>V_BK6=0CCUR^OA//?WT)AENVD)8RE\W<+%Y!\YER"Q#8
M_1'_ (-<_P#D\KQ[_P!DTD_].%I6Q_P<F_"/X>? 30/V>?@[\*/#-OH_A_P_
MX?URTTVPM8]H2-7L"6.,;W=B7=SEG=F9B68DY/\ P:X)+_PV/X\?RVVCX:R#
M?C@$ZA9X'X\_E7T&.QW]H<)U:W+9/1+R4DE^!X."P;P?$=.DW>SU?G;4_6;]
MOO\ 9)T#]MG]E;Q1^S[KFH264^IVHFTJ^AC#M;7L+"2!]NY0P\Q5W#>@8$@D
M9K^;/P?XK_:)_8$_:;AUFW76/!?COP/K'EWMG(PBFB88\R%\JZ212(<<AXY$
M<$;E89_JV( %? '_  5I_P"")GA7]NR^;XY_!;7+7PS\2K:S,=W]IB/V+Q J
MJ?+28KS#,#\HG4-E3M=6PK)\CPWG%'!REA<5_"G\[/\ R?4^LX@RNMBU'$X;
M^)'Y77_ /H+]@W_@HK^SM^WW\.+/Q5\*O%5K;^(([,2^(/!=U>)_:.DN"%?=
M'D-)#O8!9U&QPR_=;*+[]GC-?R@:EI7[4_["OQK$&H6_B_X8^.M&W&.16GT^
MZ6,ED+QNI'FP/M90REXI5SC<IK[F_9]_X.<OVN_A[:V^D?'WX5^%_B):V]JR
MM?6SMHVHW,A)(DDDB62WP <;4MDR .<Y)[,PX/Q#E[7 -5(/5:ZZ^>S.3 \4
MTHQ]GC4XR6C=OZ9^[. 1TI&("U^/A_X.N7V_\F&K_P"'/_\ O97S=^U-_P '
M#7[>/[0>DWO@_P"'U]I?PRT6ZE<;_",<IU0P$8$37TKED8=?,MT@?/?&17GT
M>$,ZJRM."CYMK]&V=M;BC*Z<;PDY/LD_U2/N#_@M[_P6,\/_   \-ZQ^Q_\
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M_@UY_8+'7XQ?%W_P?:5_\KJ_208)W 4'<>/?O7=A\VS+"TU"E5<8K9)]W?\
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MA&&UH9)?H<SX=QV4X>&*A/FB[:Q3T[?\.>)@<^P.9UGAYQY7VE;7N<)\3?\
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M]]TI'H!7Z';0>:49'%=>%S''81<M&I*-^E]#CQ&7X+%:U8)_+7[]S\JO"/\
MP:P_ .T\6WEYXY_:G\6ZCH,C-_9^FZ3H]I9W<(SQYES(9UE('7;"F?;I7NO[
M/O\ P;[?\$X_@+JR^(-9\!:S\0+^"Z6XLY?'VK+=0P;01Y?V:WC@MYT/4K/%
M)R!TK[@.>PI.2:Z:V>YMB(\LZLM?E^5CGHY-E=&5XTX_G^93T#1-)\.:9;Z%
MH.DVUC8V<*Q6=G9P+'%#&HPJ(J@!5 X  P.U7N] HKR^9][L].,8QC9+0;(
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M;,9_Z;_X5Z-2/!6,E[3F<+[I)_E9K[CSZ<>+L-'D24K;-M?G=?B'[5__  =
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MC6+S[+I-O?WD<3WLY&1%$&(,CD9.U<GCI2-'6I<O-S*VVZT9L@\X-+[5P_Q
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MM^TRL2GLEG^PG\>/B>WP^\,?M@_M-:+XT\+?#?5K;5M.TOP[X!;1KK6M2M4
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MMYSR1B<,6F$LLS2'*J0<#Y@%Q*V.NADLJ="A+V?[SG<I/2ZO>3UOU>FG<]%
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ME$T/_P!*Q7TMIW_'G#_US%%%5]A'@X7_ )'U?_#$G_QH_C_"BBI/>ZBT444
7%%%% !1WHHH!;@.E%%% !11103(__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
